Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as a 200 mg tablet for oral use. It is indicated for the medical termination of intrauterine pregnancy up to 10 weeks, for induction of labor, and, in off‑label practice, for managing Cushing’s syndrome.\n\nGNH India supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, complying with EU regulatory standards and strict quality controls.

Mifepristone is used in reproductive health and endocrine disorders where progesterone signaling is targeted.\n\n- Medical termination of intrauterine pregnancy up to 10 weeks: induces uterine contractions and embryo detachment to achieve complete abortion.\n- Induction of labor: facilitates cervical ripening and uterine activity in selected obstetric situations.\n- Cushing's syndrome (off‑label): reduces cortisol production by antagonizing progesterone receptors in adrenal tissue.

Mifepristone may cause a range of adverse reactions, varying from mild to severe.\n\nCommon Side Effects:\n- Nausea: mild gastrointestinal upset.\n- Vaginal bleeding: irregular or heavy bleeding.\n- Abdominal pain: cramping in the lower abdomen.\n- Fatigue: feeling of tiredness.\n\nSerious or Rare Side Effects:\n- Severe infection: signs of sepsis or fever.\n- Heavy or prolonged bleeding: may require medical intervention.\n- Liver dysfunction: elevated enzymes or jaundice.

Before prescribing Mifegyne, clinicians should consider several safety measures.\n\n- Confirm gestational age: ensure pregnancy is ≤10 weeks before use.\n- Assess contraindications: avoid in chronic adrenal failure, anticoagulant therapy, or severe anemia.\n- Monitor vital signs: watch for excessive bleeding or infection.\n- Provide follow‑up: schedule ultrasound to confirm complete abortion.\n- Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Mifegyne can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- Anticoagulants: increased risk of bleeding.\n- CYP3A4 inducers: may reduce efficacy of mifepristone.\n- Corticosteroids: may blunt therapeutic effect.\n\nModerate Interactions (Monitor Closely):\n- NSAIDs: may increase gastrointestinal irritation.\n- Antihypertensives: possible blood pressure changes.\n- Rifampin and other strong enzyme inducers: may affect drug metabolism.